NCT03906058

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Open-Label, Phase Ⅱ Study of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of no Less Than Second-line Chemotherapy or Targeted Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Anlotinib	All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .

Timeline

• Start date: 2019-04-29
• Primary completion: 2021-02-27
• Completion: 2022-04-30
• First posted: 2019-04-08
• Last updated: 2023-10-25

Locations

1 site across 1 country: China